Allergan took an R&D hit this quarter as it emerged from analysts that a Phase II test of dermatology med VTP-38543, acquired as part of a $640 million…

It’s that time of year when biopharmas sneak out negative R&D news amid a swath of financial data, and the FierceBiotech team has delved deep into the…

The candidate just won a breakthrough designation from the FDA and priority medicine status from the EMA in July, with an FDA submission expected next year.

Acceleron has brought in a top commercial exec from Bayer, Habib Dable, to lead the company as it aims to plan for a marketed product.

Mologen is seeking to raise €16 million to fund a suite of trials of its TLR9 agonist in patients with colorectal cancer, small cell lung cancer and HIV.

Abivax's share price has surged more than 160% in a little more than one trading session on the back of news regarding its HIV collaboration.

Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

PixarBio hopes to have an FDA-approved, non-addictive pain treatment that would offer a viable alternative to morphine by 2018. The company is reverse merging…

A snapshot survey of biotech chiefs during the second quarter has shown that their confidence to be able to raise funds has doubled since Q1, but they are a…

Financials